ArticleBMC neurology2026
Aging-related gene signatures as potential biomarkers in ischemic stroke: an integrated bioinformatics and machine learning study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Establishment of a machine learning prediction model for Wallerian degeneration after ischemic stroke.Frontiers in medicine · 2026Article
- Development and validation of a machine learning model for predicting adverse prognosis in Wallerian degeneration patients based on clinical and imaging data.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIschemic stroke (IS) and aging share similar pathophysiological features, including vascular dysfunction, inflammatory responses, and oxidative stress. However, the underlying molecular mechanisms remain unclear. This study aimed to identify key shared drive genes between IS and aging through integrated multi-omics analysis and machine learning approaches, and to explore their diagnostic and therapeutic potential.
methodsBased on the GSE22255 and GSE58294 datasets, differentially expressed genes (DEGs) associated with IS were screened using differential expression analysis and weighted gene co-expression network analysis (WGCNA). The overlapping genes between IS-related DEGs and aging-related genes (ARGs) were identified as aging-related DEGs (ARDEGs). Further refinement of core genes was performed through Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, protein-protein interaction (PPI) network construction, and machine learning algorithms (LASSO regression and support vector machine [SVM]). Immune cell infiltration was evaluated using CIBERSORT, and gene expression patterns were validated via the DISCO single-cell database. Finally, molecular docking and drug database screening were employed to predict potential therapeutic targets.
resultsA total of 279 IS-related DEGs were identified, among which 29 showed significant overlap with ARGs (ARDEGs). WGCNA revealed that the MEcyan module exhibited a strong negative correlation with IS phenotypes (r = -0.63). Machine learning algorithms identified JUP, UQCRC1, and MRPL41 as core potential diagnostic biomarkers, with area under the curve (AUC) values all exceeding 0.7. Immune infiltration analysis demonstrated a significant increase in M1 macrophages and neutrophils, along with a reduction in CD8+ T cells in IS patients. Single-cell data confirmed the specific expression of these core genes in neurons and immune cells. Molecular docking suggested that the herbicide atrazine may target these genes (binding energy < -5.7 kcal/mol), while hsa-miR-30c-5p was predicted to regulate JUP and UQCRC1.
conclusionThis study elucidates key shared genes and immune microenvironment features between IS and aging, proposing JUP, UQCRC1, and MRPL41 as potential diagnostic biomarkers. Furthermore, atrazine was identified in silicoas a potential interacting molecule, suggesting the druggability of these target proteins and providing a starting point for future drug discovery efforts in IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.